Sign in
CompletedPhase 1

Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Milwaukee, Morgantown, New York, Orlando, Rochester, and Sioux Falls, United StatesSee the 6 sitesAlso in 8 other countries, 18 sites
Status
Completed
Phase
Phase 1
People taking part
41 people enrolled
Started
17 Apr 2020
Ended
14 Sept 2024
Type of study
Interventional, 5 groups
Treatments tested
  • Ceftolozane/Tazobactam
Record updated
22 September 2025

Who can take part

Age
7 days to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Is hospitalized and anticipated to receive a minimum of 8 days of concomitant standard-of-care [SOC] antibiotic therapy for proven or suspected NP
  • If male, is abstinent from heterosexual intercourse, or agrees to use contraception during the intervention period and for ≥30 days after the last dose of study intervention
  • If female, is not pregnant or breastfeeding, or is not a woman of childbearing potential (WOCBP), or is a WOCBP using acceptable contraception, is a WOCBP with negative urine or serum pregnancy test within 48 hours of the first dose of study intervention, or is abstinent from heterosexual intercourse

Who cannot take part

  • Is receiving or is anticipated to receive piperacillin/tazobactam while receiving ceftolozane/tazobactam or has received piperacillin/tazobactam within 24 hours prior to the first dose of ceftolozane/tazobactam
  • Has participated in any clinical study of a therapeutic investigational product within 30 days prior to the first dose of ceftolozane/tazobactam
  • Has previous participation in any study of ceftolozane or ceftolozane/tazobactam
  • Has a documented history of any moderate or severe hypersensitivity (or allergic) reaction to any β-lactam antibacterial
  • Has any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the participant or the quality of study data
  • Has any rapidly progressing disease or immediately life-threatening illness including acute hepatic failure or septic shock
  • Participants 3 months to <18 years of age: has moderate to severe impairment of renal function, defined as an estimated creatinine clearance (CrCL) <50 mL/min/1.73 m2 based on the revised Schwartz equation or requirement for peritoneal dialysis, hemodialysis, or hemofiltration
  • Participants <3 months of age: has CrCL <20 mL/min/1.73 m2 based on the revised Schwartz equation or requirement for peritoneal dialysis, hemodialysis, or hemofiltration
  • Has active immunosuppression

Where in United States

Also in 8 other countries, 18 sites

  • Children's Wisconsin (Site 1321)Milwaukee, United States
  • West Virginia University (Site 1310)Morgantown, United States
  • Montefiore Medical Center [Bronx, NY] (Site 1313)New York, United States
  • AdventHealth Orlando (Site 1318)Orlando, United States
  • Mayo Clinic in Rochester, Minnesota (Site 1322)Rochester, United States
  • Sanford Children's Hospital (Site 1301)Sioux Falls, United States

About the trial

What the trial wants to find out

This is a phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia (NP).

The 5 groups in the trial

  • Group 1: Ceftolozane/Tazobactam 12 to <18 Years of AgeTreatment being tested

    Participants 12 to \<18 years of age with nosocomial pneumonia receive intravenous (IV) ceftolozane/tazobactam every 8 hours for 8-14 days.

    Treatment: Ceftolozane/Tazobactam

  • Group 2: Ceftolozane/Tazobactam 7 to <12 Years of AgeTreatment being tested

    Participants 7 to \<12 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.

    Treatment: Ceftolozane/Tazobactam

  • Group 3: Ceftolozane/Tazobactam 2 to <7 Years of AgeTreatment being tested

    Participants 2 to \<7 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.

    Treatment: Ceftolozane/Tazobactam

  • Group 4: Ceftolozane/Tazobactam 3 Months to <2 Years of AgeTreatment being tested

    Participants 3 months to \<2 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.

    Treatment: Ceftolozane/Tazobactam

  • Group 5: Ceftolozane/Tazobactam Birth to <3 Months of AgeTreatment being tested

    Participants from birth to \<3 months of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.

    Treatment: Ceftolozane/Tazobactam

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 1, Open-label, Non-comparative, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ceftolozane/Tazobactam (MK-7625A) in Pediatric Participants With Nosocomial Pneumonia
Record updated
22 September 2025